Peng Wang

Peng Wang

Auto-generated profile, based on publicly available information

Peng Wang

Univ Kentucky, Div Med Oncol, Lexington, KY 40536 USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Genes & Cancer
Verified
Journal Article
Open access
PWPeng Wang
Peng Wang
RBRavshan Burikhanov
Ravshan Burikhanov
RJRani Jayswal
Rani Jayswal
HWHeidi L. Weiss
Heidi L. Weiss
SASusanne M. Arnold
Susanne M. Arnold
VRVivek M. Rangnekar
Vivek M. Rangnekar
Chloroquine and hydroxychloroquine (HCQ) are robust inducers of the tumor suppressor Par-4 secretion from normal cells. Secreted Par-4 causes paracrine apoptosis of tumor cells and inhibits metastasis in mice. We report the clinical results with pharmacodynamic analyses of our Phase I trial using neoadjuvant administration of HCQ in patients with surgically removable early stage solid tumors. This was a single-institution trial of oral HCQ (200 or 400 mg twice daily) given for 14 days prior to planned surgery. Dose escalation was based on isotonic regression to model safety and biological effect based on plasma Par-4 analysis. Eight of the nine patients treated with HCQ showed elevation in plasma Par-4 levels over basal levels. No toxicities were observed with these dose regimens. The resected tumors from the eight HCQ-treated patients with elevated plasma Par-4 levels, but not the resected tumor from the patient who failed to induce plasma Par-4 levels, exhibited TUNEL-positivity indicative of apoptosis. Resected tumors from all nine HCQ-treated patients showed p62/sequestosome-1 induction indicative of autophagy-inhibition by HCQ. Our findings indicate that both dose levels of HCQ were well-tolerated and that Par-4 secretion but not induction of the autophagy-inhibition marker p62 correlated with apoptosis induction in patients' tumors.

29 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ZMZin Myint
Zin Myint
RSramon sun
ramon sun
PHPatrick Hensley
Patrick Hensley
AJAndrew C. James
Andrew C. James
PWPeng Wang
Peng Wang
DADerek B Allison
Derek B Allison
High Glutaminase (GLS1) expression may have prognostic implications in colorectal and breast cancers; however, high quality data for expression in prostate cancer (PCa) are lacking. The purpose of this study is to investigate the status of GLS1 expression in PCa and correlated expression levels with clinicopathologic parameters. This study was conducted in two phases: an exploratory cohort analyzing RNA-Seq data for GLS1 from The Cancer Genome Atlas (TCGA) data portal (246 PCa samples) and a GLS1 immunohistochemical protein expression cohort utilizing a tissue microarray (TMA) (154 PCa samples; 41 benign samples) for correlation with clinicopathologic parameters. In the TCGA cohort, GLS1 mRNA expression did not show a statistically significant difference in disease-free survival (DFS) but did show a small significant difference in overall survival (OS). In the TMA cohort, there was no correlation between GLS1 expression and stage, Gleason score, DFS and OS. GLS1 expression did not significantly correlate with the clinical outcomes measured; however, GLS1 expression was higher in PCa cells compared to benign epithelium. Future studies are warranted to evaluate expression levels in greater numbers of high-grade and advanced PCa samples to investigate whether there is a rational basis for GLS1 targeted therapy in a subset of patients with prostate cancer.

3 January 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ZZZhengqiu Zhou
Zhengqiu Zhou
CKConnor Kinslow
Connor Kinslow
PWPeng Wang
Peng Wang
BHBin Huang
Bin Huang
SCSimon Cheng
Simon Cheng
RSramon sun
ramon sun
Clear cell adenocarcinoma (CCA) is a rare variant of urinary bladder carcinoma with a glycogen-rich phenotype and unknown prognosis. Using the National Cancer Institute’s surveillance, epidemiology, and end results (SEER) program database, we documented recent trends in incidence, mortality, demographical characteristics, and survival on this rare subtype of urinary bladder cancer. The overall age-adjusted incidence and mortality of CCA was 0.087 (95% confidence interval (CI): 0.069–0.107) and 0.064 (95% CI: 0.049–0.081) respectively per million population. In comparison to non-CCAs, CCAs were more commonly associated with younger age (<60 years old, p = 0.005), female (p < 0.001), black ethnicity (p = 0.001), grade III (p < 0.001), and higher AJCC 6th staging (p < 0.001). In addition, CCA patients more frequently received complete cystectomy (p < 0.001) and beam radiation (p < 0.001) than non-CCA patients. Our study showed a poorer prognosis of CCAs compared to all other carcinomas of the urinary bladder (p < 0.001), accounted for by higher tumor staging of CCA cases. This study adds to the growing evidence that glycogen-rich cancers may have unique characteristics affecting tumor aggressiveness and patient prognosis. Additional mechanistic studies are needed to assess whether it’s the excess glycogen that contributes to the higher stage at diagnosis.

4 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CLCharles T. Lutz
Charles T. Lutz
LLLydia Livas
Lydia Livas
SPSteven R. Presnell
Steven R. Presnell
MSMorgan Sexton
Morgan Sexton
PWPeng Wang
Peng Wang
Men are more likely to develop cancer than women. In fact, male predominance is one of the most consistent cancer epidemiology findings. Additionally, men have a poorer prognosis and an increased risk of secondary malignancies compared to women. These differences have been investigated in order to better understand cancer and to better treat both men and women. In this review, we discuss factors that may cause this gender difference, focusing on urothelial bladder cancer (UBC) pathogenesis. We consider physiological factors that may cause higher male cancer rates, including differences in X chromosome gene expression. We discuss how androgens may promote bladder cancer development directly by stimulating bladder urothelium and indirectly by suppressing immunity. We are particularly interested in the role of natural killer (NK) cells in anti-cancer immunity.

12 May 2019 in Rural and Remote Health
Verified
Journal Article
Open access
ZMZin Myint
Zin Myint
RORichard O'Neal
Richard O'Neal
QCQuan Chen
Quan Chen
BHBin Huang
Bin Huang
RVRobin Vanderpool
Robin Vanderpool
PWPeny Wang
Peny Wang
RRH: Rural and Remote Health. Published article number: 4989 - Disparities in prostate cancer survival in Appalachian Kentucky: a population-based study

1 March 2022
Verified
Journal Article
Closed access
YAYanal Alnimer
Yanal Alnimer
AQAyman Qasrawi
Ayman Qasrawi
DYDonglin Yan
Donglin Yan
PWPeng Wang
Peng Wang
Purpose: Cytoreductive nephrectomy (CN) was considered a well-established treatment modality for patients with metastatic renal cell carcinoma (RCC) in the interferon era. However, its role after the introduction of multiple targeted therapies is less well established. Herein, We evaluated the effect of CN on overall survival (OS) on pa-tients with RCC who were identified through the Surveillance, Epidemiology, and End Results database (SEER). Materials and Methods: A total of 5,483 patients with metastatic RCC were identified from 2010 to 2016 using the SEER database. Factors pertaining to the following variables were collected: presence or absence of CN; age; gender; grade; status of metastasis to bone, liver, lung and brain; tumor stage; nodal status; histological subtypes; and chemotherapy status. Subjects who had CN were matched with those who did not in all previously mentioned covariates using inverse probability weighting. These weights were then used in adjusted Cox regression models to report doubly robust estimates. Results: CN was associated with 67% reduction in the hazards of death. Advanced T-stage, N1 disease, advanced tumor grade, non-clear histology and metastasis to bone, liver, lung or brain are independent risk factors for death. Patients with T4 disease benefited less of CN compared to those with T1 disease, while higher number of metastat -ic sites didn???t predict worse outcome among those who had CN. Conclusion: CN could provide a survival advantage in favorable risk patients with RCC in the era of targeted therapy.